We’re Turning Science into Solutions A Deep Legacy of Innovation—As One for Patients EMD Serono is the U.S. healthcare business of Merck KGaA, Darmstadt, Germany - a global science and tech company with a legacy of using science as a force for good. We’re fueled for the future, lev...
EMD Serono is the U.S. healthcare business of Merck KGaA, Darmstadt, Germany - a global science and tech company with a legacy of using science as a force for good. We’re fueled for the future, leveraging our expertise to address unmet medical needs and impact the lives of patients who...
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and electronics.
Suresh Martha works at the intersection of two industries that are rapidly evolving with advancements in AI: business intelligence and biopharma/healthcare. He is the head of data-driven innovation and analytics at EMD Serono—the healthcare business of Merck KGaA, Darmstadt, Germany in the United...
使用说明-EMDSeronoInc 下载积分: 4000 内容提示: (注射用促卵泡激素α)皮下注射用处方药使用说明EMD Serono,Inc. 是德国达姆施塔特 Merck KGaA 的子公司300 IU / 0.5 mL 450 IU / 0.75 mL 300 IU / 0.5 mL 文档格式:PDF | 页数:50 | 浏览次数:50 | 上传日期:2017-08-30 02:40:58 | 文档星级: ...
2/3,德国默克(Merck KGaA)旗下EMD Serono宣布,美国FDA已加速批准口服MET抑制剂Tepmetko(tepotinib)上市,用于治疗携带MET外显子14(METex14)跳跃变异的转移性非小细胞肺癌(NSCLC)成人患者。 Tepmetko是...
Merck KGaA subsidiary EMD Serono and Mersana Therapeutics announced that the companies have agreed to co-develop next-generation antibody-drug conjugates (ADCs). ADCs, which comprise an antibody linked to cytotoxic drugs, zero in on the cancer cells and deliver the cytotoxic drug to increase the ...
使用说明-EMDSeronoInc.PDF,(注射用促卵泡激素α) 300 IU / 0 .5 mL 450 IU / 0 .75 mL 300 IU / 0 .5 mL 皮下注射用 处方药 使用说明 EMD Serono ,Inc . 是德国达姆施塔特 Merck KGaA 的子公司 2 使用说明 GONAL-f® (果纳芬) RFF Redi-ject™ (注射用促卵泡激素α)
EMD Serono is dedicated to researching meaningful solutions for patients impacted by select endocrine disorders such as HIV-associated wasting.